keyword
MENU ▼
Read by QxMD icon Read
search

Ccrcc

keyword
https://www.readbyqxmd.com/read/28435451/ahnak2-is-a-novel-prognostic-marker-and-oncogenic-protein-for-clear-cell-renal-cell-carcinoma
#1
Minglei Wang, Xuefeng Li, Jin Zhang, Qiong Yang, Wenqi Chen, Weilin Jin, Yi-Ran Huang, Ru Yang, Wei-Qiang Gao
Integrative database analysis was performed to identify novel candidate oncogene AHNAK2 overexpressed in clear cell renal cell carcinoma (ccRCC). However, the function of AHNAK2 in cancer cells is currently unknown. In this study, we first confirmed the upregulation of AHNAK2 in ccRCC tissues compared with adjacent normal tissues in 15 pairs of samples. Then we analyzed AHNAK2 expression in a large cohort of ccRCC patient samples (n = 355), and found that up-regulation of AHNAK2 was positively correlated with tumor progression and poor survival (p = 0...
2017: Theranostics
https://www.readbyqxmd.com/read/28432832/profiling-microrna-from-nephrectomy-and-biopsy-specimens-predictors-of-progression-and-survival-in-clear-cell-renal-cell-carcinoma
#2
Casey G Kowalik, Drew A Palmer, Travis B Sullivan, Patrick A Teebagy, John M Dugan, John A Libertino, Eric J Burks, David Canes, Kimberly M Rieger-Christ
OBJECTIVE: To identify miRNA characteristic of metastatic clear cell renal cell carcinoma (ccRCC) and those indicative of cancer specific survival in nephrectomy and biopsy specimens. We also sought to determine if a miRNA panel could differentiate benign from ccRCC tissue. MATERIALS AND METHODS: RNA was isolated from nephrectomy and kidney biopsy specimens (n=156; n=46 respectively). Samples were grouped: benign, non-progressive and progressive ccRCC. MiRNA were profiled by microarray and validated by qRT-PCR...
April 22, 2017: BJU International
https://www.readbyqxmd.com/read/28432616/prognostic-impact-of-pd-1-and-its-ligands-in-renal-cell-carcinoma
#3
REVIEW
Franziska Erlmeier, Wilko Weichert, Andres Jan Schrader, Michael Autenrieth, Arndt Hartmann, Sandra Steffens, Philipp Ivanyi
Programmed death-1 receptor (PD-1) and programmed death-1 receptor-ligand (PD-L1) have been suggested to play a role as prognostic markers in clear cell renal cell carcinoma (ccRCC). The association between PD-L1 and prognosis seems to be more robust than for PD-1. Further, preliminary analyses suggest that neither PD-1 nor its ligands play a role as prognostic markers in non-clear cell RCC, while the prognostic role of PD-L2 in ccRCC as well as in non-clear cell RCC remains unclear.
June 2017: Medical Oncology
https://www.readbyqxmd.com/read/28427219/high-truncated-o-glycan-score-predicts-adverse-clinical-outcome-in-patients-with-localized-clear-cell-renal-cell-carcinoma-after-surgery
#4
SonTung NguyenHoang, Yidong Liu, Le Xu, Lin Zhou, Yuan Chang, Qiang Fu, Zheng Liu, Zongming Lin, Jiejie Xu
Truncated O-glycans, including Tn-antigen, sTn-antigen, T-antigen, sT-antigen, are incomplete glycosylated structures and their expression occur frequently in tumor tissue. The study aims to evaluate the abundance of each truncated O-glycans and its clinical significance in postoperative patients with localized clear-cell renal cell carcinoma (ccRCC). We used immunohistochemical testing to analyze the expression of truncated O-glycans in tumor specimens from 401 patients with localized ccRCC. Truncated-O-glycan score was built by integrating the expression level of Tn-, sTn- and sT-antigen...
March 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28427214/high-mucin-5ac-expression-predicts-adverse-postoperative-recurrence-and-survival-of-patients-with-clear-cell-renal-cell-carcinoma
#5
Haijian Zhang, Yidong Liu, Huyang Xie, Weisi Liu, Qiang Fu, Dengfu Yao, Jiejie Xu, Jianxin Gu
BACKGROUND: Mucin 5AC (MUC5AC), as a member of secreted/gel-forming mucin family, was frequently found to be abnormally expressed in inflammation or malignant diseases. However, the clinic pathologic features and prognostic values of MUC5AC in clear-cell renal cell carcinoma (ccRCC) have not been reported up to now. METHODS: MUC5AC expression was analyzed by immunohistochemistry on tissue microarrays. Kaplan-Meier survival curves, Univariate and Multivariate Cox analysis and newly-established nomogram model were performed to evaluate the prognostic value...
March 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28423633/novel-lincrna-slinky-is-a-prognostic-biomarker-in-kidney-cancer
#6
Xue Gong, Zurab Siprashvili, Okyaz Eminaga, Zhewei Shen, Yusuke Sato, Haruki Kume, Yukio Homma, Seishi Ogawa, Paul A Khavari, Jonathan R Pollack, James D Brooks
Clear cell renal cell carcinomas (ccRCC) show a broad range of clinical behavior, and prognostic biomarkers are needed to stratify patients for appropriate management. We sought to determine whether long intergenic non-coding RNAs (lincRNAs) might predict patient survival. Candidate prognostic lincRNAs were identified by mining The Cancer Genome Atlas (TCGA) transcriptome (RNA-seq) data on 466 ccRCC cases (randomized into discovery and validation sets) annotated for ~21,000 lncRNAs. A previously uncharacterized lincRNA, SLINKY (Survival-predictive LINcRNA in KidneY cancer), was the top-ranked prognostic lincRNA, and validated in an independent University of Tokyo cohort (P=0...
March 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/28423523/mir-106b-5p-promotes-renal-cell-carcinoma-aggressiveness-and-stem-cell-like-phenotype-by-activating-wnt-%C3%AE-catenin-signalling
#7
Jun Lu, Jin-Huan Wei, Zi-Hao Feng, Zhen-Hua Chen, Yong-Qian Wang, Yong Huang, Yong Fang, Yan-Ping Liang, Jun-Jie Cen, Yi-Hui Pan, Bing Liao, Wen-Fang Chen, Wei Chen, Jun-Hang Luo
PURPOSE: To examine the role of miR-106b-5p in regulating the cancer stem-cell-like phenotype in clear cell renal cell carcinomas (ccRCC). EXPERIMENTAL DESIGN: Real-time PCR was performed to evaluate miR-106b-5p levels in ccRCC cell lines and patients specimens. A series of in vivo and in vitro assays were performed to confirm the effect of miR-106b-5p on ccRCC stemness phenotype. RESULTS: ccRCC cells and tissues expressed more miR-106b-5p than normal controls...
March 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28421649/decreased-expression-of-epha5-is-associated-with-fuhrman-nuclear-grade-and-pathological-tumour-stage-in-ccrcc
#8
Xiaolin Wang, Haifei Xu, Zhijun Wu, Xiao Chen, Jiandong Wang
The incidence of renal cell carcinoma is increasing all over the world. The molecular mechanisms for tumorigenesis, progression and prognosis are still unknown. The erythropoietin-producing hepatoma amplified sequence (Eph) receptors have been reported to be expressed aberrantly in many types of human cancers and in particular EphA5 may play a role in certain human cancers. In this study, a set of clear cell renal cell carcinoma (ccRCC) tissues were subjected to immunohistochemistry. The relationship between EphA5 protein expression and clinicopathological parameters was statistically analysed...
April 19, 2017: International Journal of Experimental Pathology
https://www.readbyqxmd.com/read/28418903/kinomic-profiling-identifies-focal-adhesion-kinase-1-as-a-therapeutic-target-in-advanced-clear-cell-renal-cell-carcinoma
#9
Arindam P Ghosh, Christopher D Willey, Joshua C Anderson, Karim Welaya, Dongquan Chen, Amitkumar Mehta, Pooja Ghatalia, Ankit Madan, Gurudatta Naik, Sunil Sudarshan, Guru Sonpavde
The introduction of targeted therapies has caused a paradigm shift in the treatment of metastatic clear cell (cc)-renal cell carcinoma (RCC). We hypothesized that determining differential kinase activity between primary and metastatic tumor sites may identify critical drivers of progression and relevant therapeutic targets in metastatic disease. Kinomic profiling was performed on primary tumor and metastatic tumor deposits utilizing a peptide substrate microarray to detect relative tyrosine phosphorylation activity...
March 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28418894/urinary-rkip-p-rkip-is-a-potential-diagnostic-and-prognostic-marker-of-clear-cell-renal-cell-carcinoma
#10
Massimo Papale, Grazia Vocino, Giuseppe Lucarelli, Monica Rutigliano, Margherita Gigante, Maria Teresa Rocchetti, Francesco Pesce, Francesca Sanguedolce, Pantaleo Bufo, Michele Battaglia, Giovanni Stallone, Giuseppe Grandaliano, Giuseppe Carrieri, Loreto Gesualdo, Elena Ranieri
Clear cell Renal Cell Carcinoma (ccRCC) causes over 13,000 deaths each year, and about 20,000 new cases/year in Europe. In most cases, the causes are unknown and, most importantly, there are no reliable biomarkers for the diagnosis and prognosis of this disease. The search for sensitive biomarkers for early diagnosis and prognosis of clear cell Renal Cell Carcinoma (ccRCC) is currently a fast growing field. We carried out proteomics analysis of 93 urinary samples of healthy subjects (HS) and patients affected by ccRCC, prostate cancer (PCa) and chronic kidney disease (CKD), that was able to successfully distinguish each group...
March 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28414866/characterizing-the-outcomes-of-metastatic-papillary-renal-cell-carcinoma
#11
John Connor Wells, Frede Donskov, Anna P Fraccon, Felice Pasini, Georg A Bjarnason, Benoit Beuselinck, Jennifer J Knox, Sun Young Rha, Neeraj Agarwal, Isaac Alex Bowman, Jae-Lyun Lee, Sumanta K Pal, Sandy Srinivas, Douglas Scott Ernst, Ulka N Vaishampayan, Lori A Wood, Robin Simpson, Guillermo De Velasco, Toni K Choueiri, Daniel Y C Heng
Outcomes of metastatic papillary renal cell carcinoma (pRCC) patients are poorly characterized in the era of targeted therapy. A total of 5474 patients with metastatic renal cell carcinoma (mRCC) in the International mRCC Database Consortium (IMDC) were retrospectively analyzed. Outcomes were compared between clear cell (ccRCC; n = 5008) and papillary patients (n = 466), and recorded type I and type II papillary patients (n = 30 and n = 165, respectively). Overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) favored ccRCC over pRCC...
April 16, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28410911/comprehensive-analysis-of-survival-outcomes-in-non-clear-cell-renal-cell-carcinoma-patients-treated-in-clinical-trials
#12
Guillermo de Velasco, Rana R McKay, Xun Lin, Raphel B Moreira, Ronit Simantov, Toni K Choueiri
BACKGROUND: Clinical data from patients with non-clear cell renal cell carcinoma (nccRCC) receiving targeted therapy are limited, and many clinical trials have excluded these patients from study entry. We sought to investigate the outcomes of patients with nccRCC treated in clinical trials in the modern era compared with the outcomes of patients with clear cell RCC (ccRCC). PATIENTS AND METHODS: We conducted a retrospective study of patients with metastatic RCC who had received targeted therapy in Pfizer-sponsored phase II and III clinical trials from 2003 to 2013...
March 21, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28408296/percutaneous-radiofrequency-ablation-for-renal-cell-carcinoma-vs-partial-nephrectomy-comparison-of-long-term-oncologic-outcomes-in-both-clear-cell-and-non-clear-cell-of-the-most-common-subtype
#13
Ning Liu, Daoguang Huang, Xiangming Cheng, Yankun Chong, Wei Wang, Weidong Gan, Hongqian Guo
OBJECTIVES: To compare the clinical outcomes of percutaneous radiofrequency ablation (PRFA) and partial nephrectomy (PN) in patients with clear cell renal cell carcinoma (ccRCC) and non-clear cell RCC (nccRCC) of the most common subtypes. MATERIALS AND METHODS: A retrospective study was conducted to review the records of all the patients who underwent PRFA or PN between February 2005 and April 2014 at our institution. Patients with histologic confirmation of ccRCC, papillary RCC, and chromophobe RCC were included...
April 10, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28408295/genomic-alterations-as-predictors-of-survival-among-patients-within-a-combined-cohort-with-clear-cell-renal-cell-carcinoma-undergoing-cytoreductive-nephrectomy
#14
Daniel M Tennenbaum, Brandon J Manley, Emily Zabor, Maria F Becerra, Maria I Carlo, Jozefina Casuscelli, Almedina Redzematovic, Nabeela Khan, Maria E Arcila, Martin H Voss, Darren R Feldman, Robert J Motzer, Nicole E Benfante, Jonathan A Coleman, Paul Russo, James J Hsieh, Abraham Ari Hakimi
PURPOSE: To establish prognostic genomic biomarkers for patients with metastatic clear cell renal cell carcinoma (ccRCC). MATERIALS AND METHODS: We identified 60 patients who presented with metastatic ccRCC at our institution between 2001 and 2015 and had genomic sequencing on their primary tumor. We pooled these patients with 107 other patients with the same inclusion criteria from three well-known public databases. Five commonly mutated genes were chosen for analysis: VHL, PBRM1, BAP1, SETD2, and KDM5C...
April 10, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28404888/ecto-5-nucleotidase-cd73-is-a-biomarker-for-clear-cell-renal-carcinoma-stem-like-cells
#15
Lei Song, Wenling Ye, Yong Cui, Jianzhong Lu, Yanan Zhang, Nan Ding, Wentao Hu, Hailong Pei, Zhongjin Yue, Guangming Zhou
Identification of a specific biomarker for cancer stem cells (CSCs) is of potential applications in the development of effective therapeutic strategies for renal cell carcinoma (RCC). In this study, both the RCC cell line 786-O and surgically removed clear cell RCC (ccRCC) tissues were implemented to grew as spheroids in serum-free medium supplemented with mitogens. This subpopulation possessed key characteristics defining CSCs. We also identified that surgically removed ccRCC tissues were heterogenic and there was a subpopulation of cells that was highly stained with rhodamine-123...
March 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28396841/ubiquitin-ligase-smurf1-functions-as-a-prognostic-marker-and-promotes-growth-and-metastasis-of-clear-cell-renal-cell-carcinoma
#16
Mang Ke, Licai Mo, Weilin Li, Xianjun Zhang, Feiping Li, Hongyuan Yu
Smad ubiquitin regulatory factor 1 (SMURF1), a recently identified E3 ubiquitin ligase, targets substrate proteins for ubiquitination and proteasomal degradation. Previous studies have reported that SMURF1 also functions as an oncogene in human cancers. However, the clinical value of SMURF1 and its role in clear cell renal cell carcinoma (ccRCC) are unknown. SMURF1 expression was analyzed in 100 cases of ccRCC and matched tumor-adjacent specimens. SMURF1 was prominently overexpressed in ccRCC specimens compared with tumor-adjacent specimens...
April 2017: FEBS Open Bio
https://www.readbyqxmd.com/read/28385150/combination-of-serum-histidine-and-plasma-tryptophan-as-a-potential-biomarker-to-detect-clear-cell-renal-cell-carcinoma
#17
Hyung-Ok Lee, Robert G Uzzo, Debra Kister, Warren D Kruger
BACKGROUND: In previous work, we showed that serum-free amino acid (SFAA) profiles were different between kidney cancer patients and age and sex matched controls. The goals of the current study are to: (1) confirm our initial observation on an independent sample set; (2) examine if there were similar differences in plasma-free amino acids (PFAA); and (3) determine if removal of tumors changed SFAA and PFAA profiles. METHODS: SFAA and PFAA profiles were measured in 484 samples taken from 124 healthy controls and 56 clear cell renal cell carcinoma (ccRCC) patients both before and after resection of renal tumors...
April 6, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28376281/differentiation-of-fat-poor-angiomyolipoma-from-clear-cell-renal-cell-carcinoma-in-contrast-enhanced-mdct-images-using-quantitative-feature-classification
#18
Han Sang Lee, Helen Hong, Dae Chul Jung, Seunghyun Park, Junmo Kim
PURPOSE: To develop a computer-aided classification system to differentiate benign fat-poor angiomyolipoma (fp-AML) from malignant clear-cell renal cell carcinoma (ccRCC) using quantitative feature classification on histogram and texture patterns from contrast-enhanced multi-detector computer tomography (CE MDCT) images. METHODS: A dataset including 50 CE MDCT images of 25 fp-AML and 25 ccRCC patients was used. From these images, the tumors were manually segmented by an expert radiologist to define the regions of interest (ROI)...
April 4, 2017: Medical Physics
https://www.readbyqxmd.com/read/28374447/the-utility-of-using-immunohistochemistry-in-the-differentiation-of-metastatic-cutaneous-clear-cell-renal-cell-carcinoma-and-clear-cell-hidradenoma
#19
Moises J Velez, Courtney L Thomas, Jason Stratton, Wilma Bergfeld, Joshua Weaver
BACKGROUND: Clear cell hidradenoma and cutaneous clear cell renal cell carcinoma (CCRCC) overlap morphologically. The distinction may be difficult in a patient with a history of CCRCC, presenting with a cutaneous nodule, potentially leading to an erroneous diagnosis. We investigated the usefulness of napsin A and paired box gene 8 (PAX-8) with previously studied markers epithelial membrane antigen (EMA), carcinoembryonic antigen (CEA), vimentin and CD 10 in differentiating CCRCC from hidradenoma...
April 4, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/28367246/overexpression-of-g6pd-represents-a-potential-prognostic-factor-in-clear-cell-renal-cell-carcinoma
#20
Qiao Zhang, Xiaojia Yi, Zhe Yang, Qiaoqiao Han, Xuesong Di, Fufei Chen, Yanling Wang, Zihan Yi, Yingmin Kuang, Yuechun Zhu
Glucose-6-phosphate dehydrogenase (G6PD) participates in glucose metabolism and it acts as the rate-limiting enzyme of the pentose phosphate pathway (PPP). Recently, G6PD dysregulation has been found in a variety of human cancers. Through analyzing published data in The Cancer Genome Atlas (TCGA), our pilot study indicated that G6PD mRNA expression was significantly higher in advanced Fuhrman grade in clear cell renal cell carcinoma (ccRCC). These clues promoted us to further evaluate the expression profile of G6PD and its prognostic impact in patients with ccRCC...
2017: Journal of Cancer
keyword
keyword
42598
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"